Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2007-02-27
2007-02-27
Lankford, Jr., Leon B. (Department: 1651)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C424S085400, C424S085600, C424S085700, C514S002600, C514S110000, C514S176000, C514S420000
Reexamination Certificate
active
10637869
ABSTRACT:
A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in combinations thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using an NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histiocytosis or a negative NCM skin test. Compositions and methods for eliciting an immune response to endogenous or exogenous tumor antigens.
REFERENCES:
patent: 4116951 (1978-09-01), Wang
patent: 4353821 (1982-10-01), Birr et al.
patent: 4390623 (1983-06-01), Frabricius et al.
patent: 4439196 (1984-03-01), Higuchi
patent: 4447224 (1984-05-01), DeCant, Jr. et al.
patent: 4447233 (1984-05-01), Mayfield
patent: 4464355 (1984-08-01), Fabricius et al.
patent: 4466918 (1984-08-01), Birr et al.
patent: 4470926 (1984-09-01), Birr et al.
patent: 4475196 (1984-10-01), La Zor
patent: 4486194 (1984-12-01), Ferrara
patent: 4487603 (1984-12-01), Harris
patent: 4612365 (1986-09-01), Birr et al.
patent: 4910296 (1990-03-01), Birr et al.
patent: 4925678 (1990-05-01), Ranney
patent: 4959217 (1990-09-01), Sanders et al.
patent: 5100664 (1992-03-01), Doyle et al.
patent: 5167616 (1992-12-01), Haak et al.
patent: 5169383 (1992-12-01), Gyory et al.
patent: 5225182 (1993-07-01), Sharma
patent: 5503841 (1996-04-01), Doyle et al.
patent: 5632983 (1997-05-01), Hadden
patent: 5643565 (1997-07-01), Doyle et al.
patent: 5698194 (1997-12-01), Hadden
patent: 5800810 (1998-09-01), Doyle et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 2002/0034494 (2002-03-01), Vicari, et al.
patent: 0 974 357 (1998-07-01), None
Albert et al, Nature, vol. 392, pp. 86-89 (1998). Banchereau et al, Annual Reviews of Immunology, vol. 18, pp. 767-811 (2000).
Barrera J, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW.Combination immunotherapy of squamous cell head and neck cancer: A phase 11 trial. Arch Otolaryngol Head Neck Surg 126:345-351 (2000).
Bellone, et al, Immunology Today, vol. 20, No. 10, p 457-462 (1998).
Berd D, Mastrangelo M J. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T suppressor function without depletion of the CD8+subset. Cancer Research 47:3317-3321 (1987).
Borysiewickz L K, Fiander A. Nimako M. A recombinant vaccine virus encoding human papilomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1524-1527 (1996).
Burke and Olson, “Preparation of Clone Libraries in Yeast Artificial-Chromosome Vectors” in Methods in Enzymology, vol. 194, “Guide to Yeast Genetics and Molecular Biology”, eds. C. Guthrie and G. Fink, Academic Press, Inc., Chap. 17, pp. 251-270 (1991).
Capecchi, “Altering the genome by homologous recombination” Science 244:1288-1292 (1989).
Cregg J M, Vedvick T S, Raschke W C: Recent Advances in the Expression of Foreign Genes in Pichia pastoris, Bio/Technology 11:905-910 (1993).
Dickinson et al., “High frequency gene targeting using insertional vectors”, Human Molecular Genetics, vol. 2, No. 8, pp. 1299-1302 (1993).
Duff and Lincoln, “Insertion of a pathogenic mutation into a yeast artificial chromosome containing the human APP gene and expression in ES cells”, Research Advances in Alzheimer's Disease and Related Disorders (1995).
Gilboa, E, Eglitis, M A, Kantoff, P W, Anderson, W F: Transfer and expression of cloned genes using retroviral vectors. BioTechniques 4(6):504-512 (1986). Gillis et al. (1978).
Hadden JW, Endicott J, Baekey P, Skipper P, Hadden E M. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg. 120:395-403 (1994).
Hadden JW, Saha A R, Sosa M, Hadden E M. Immunotherapy with natural interleukins and/or Thymosin α1 potently augments T lymphocyte responses of hydrocortisone-treated aged mice. Int'l J Immunopharmacol 17:821-828 (1995).
Hadden JW. Immunology and immunotherapy of breast cancer: An update: Int'l J Immunopharmacol 21:79-101 (1999).
Hadden JW. The immunopharmacology of head and neck cancer: An update. Int'l J Immunopharmacol 11/12:629-644 (1997).
Hadden JW. The treatment of zinc deficiency is an immunotherapy. Int'l J Immunopharmacol 17:696-701 (1995).
Hadden, J., E. Verastegui, J.L. Barrera, M. Kurman, A. Meneses, J.W. Zinser, J. de la Garza, and E. Hadden, “A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck,” International Immunopharmacology 3; 1073-1081 (2003).
Hadden, John W. “Immunodeficiency and cancer: prospects for correction,” Intl. Immunopharm. 3:1061-1071 (2003).
Hadden, John W. “Combination immunotherapy,” Intl. Immunopharm. 3:1049-1050 (2003).
Hank A J, Albertini M R, Sondel P M. Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease. Cancer Chemother & Biol Resp Mod 18:210-222 (1999).
Hirsch B, Johnson JT, Rabin BD, et al. Immunostimulation of patients with head and neck cancer. Arch Otolaryngol 1983; 109:298-301.
Huston et al, “Protein engineering of single-chain Fv analogs and fusion proteins” in Methods in Enzymology (J J Langone, ed.; Academic Press, New York, N.Y.) 203:46-88 (1991).
Huxley et al., “The human HPRT gene on a yeast artificial chromosome is functional when transferred to mouse cells by cell fusion”, Genomics, 9:742-750 (1991).
Jakobovits et al., “Germ-like transmission and expression of a human-derived yeast artificial chromosome”, Nature, vol. 362, pp. 255-261 (1993).
Johnson and Bird, 1991 Construction of single-chain Fvb derivatives of monoclonal antibodies and their production inEscherichia coliin Methods in Enzymology (J J Langone, ed.; Academic Press, New York, N.Y.) 203:88-99 (1989).
Kavanaugh D Y, Carbone D P. Immunologic dysfunction in cancer. Hematol-Oncol Clinics of North Amer 10(4):927-951 (1996).
Lamb et al., “Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice”, Nature Genetics, vol. 5, pp. 22-29 (1993).
Maass G, Schmidt W, Berger M, et al. Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be rquired for successful tumor vaccination. Proc Natl Acad Sci USA, 92:5540-5542 (1995).
Mackall (Stem Cells 2000, vol. 18. pp. 10-18) Mackall et al, (New England Journal of Medicine, vol. 332, pp. 143-149 (1995).
Maclean G D, Miles D W, Rubens R D, Reddish M A, Longenecker bone marrow. Enhancing the effect of Theratope STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19(4):309-316 (1996).
Marshak et al, “Strategies for Protein Purification and Characterization. A laboratory course manual.” CSHL Press (1996).
Masek, K. et al., “Neuroendocrine immune interactions in health and disease,” Intl. Immunopharm. 3:1235-1246 (2003).
Meneses A, Verastegui E, Barrera J L, Zinser J, de la Garza J, Hadden J W. Histological findings in patients with head and neck squamous cell carcinoma receiving perilympatic natural cytokine mixture prior to surgery. Arch Pathol Lab Med 122:447-454 (1998).
Meneses A, Verastegui E, Barrera J L, de la Garza J, and Hadden J W, “Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2,” International Immunopharmacology, 3; 1083-1091 (2003).
Mernaugh and Mernaugh, “An overview of phage-displayed recombinant antibodies” in Molecular Methods In Plant Pathology (R P Singh and
IRx Therapeutics, Inc.
Kohn Kenneth I.
Kohn & Associates PLLC
Lankford , Jr. Leon B.
LandOfFree
Vaccine immunotherapy for immune suppressed patients does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine immunotherapy for immune suppressed patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine immunotherapy for immune suppressed patients will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853132